In December 2005 Abgenix Inc was acquired by Amgen itself - albeit on small scale - an SBIR involved firm in its early days. Formed by Cell Genesys Inc. (Foster City, California) Abgenix was established to develop the company's human monoclonal antibodies for pharmaceutical products. Abgenix platform includes leading technologies and state-of-the-art manufacturing capabilities that enable the rapid generation, selection, and production of high affinity, fully human antibodies for a variety of disease targets. Management are leveraging our leadership position in human antibody technology to build a diversified product portfolio. Our fully integrated product development capabilities range from the generation/characterization of antibodies to full-scale production in our state-of-the-art manufacturing facility. Core to our discovery platform are XenoMouse® and XenoMaxTMproprietary technologies used to generate large pools of fully human antibodies from which to choose appropriate candidates. Once candidates are selected, they can be advanced through clinical development and commercial-scale production via proprietary cell lines and versatile process development technologies, as we leverage our process sciences plant and flexible clinical- and commercial-scale manufacturing infrastructure to streamline scale-up and minimize risks associated with biologics manufacturing.